据证券之星公开数据整理，近期泽璟制药（688266）发布2025年中报。根据财报显示，泽璟制药增收不 增利。截至本报告期末，公司营业总收入3.76亿元，同比上升56.07%，归母净利润-7280.35万元，同比 下降9.42%。按单季度数据看，第二季度营业总收入2.08亿元，同比上升57.04%，第二季度归母净利 润-4454.13万元，同比下降64.74%。 本次财报公布的各项数据指标表现一般。其中，毛利率89.67%，同比减3.31%，净利率-20.12%，同比 增37.54%，销售费用、管理费用、财务费用总计2.36亿元，三费占营收比62.8%，同比增15.17%，每股 净资产4.45元，同比减24.91%，每股经营性现金流-0.06元，同比减115.12%，每股收益-0.28元，同比减 12.0% 财务报表中对有大幅变动的财务项目的原因说明如下： 应收票据变动幅度为-100.0%,原因:票据到期收回货款。 使用权资产变动幅度为-44.77%,原因:基于房屋租赁补充合同，调整使用权资产。 其他非流动资产变动幅度为737.57%,原因:基建工程设备预付款增加。 应付票据变动幅度为72.78%,原因:银行承 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its self-developed drug, JAK inhibitor, which is indicated for adult patients with intermediate or high-risk primary myelofibrosis [1] Group 1: Drug Approval and Indications - The drug, Hydrochloride Jikaxitinib Tablets (Zepuping), is approved for use in adult patients with intermediate or high-risk primary myelofibrosis and other related diseases [1] - This drug is classified as a Class 1 new drug and works by inhibiting the JAK-STAT signaling pathway to reduce inflammation and splenomegaly [1] Group 2: Clinical Trial Results - According to Phase III clinical trials, 72.3% of participants showed a reduction in spleen volume of ≥35% from baseline after 24 weeks of treatment, indicating significant therapeutic benefits [1] Group 3: Clinical Guidelines - Hydrochloride Jikaxitinib Tablets have been included in the "2024 Guidelines for the Diagnosis and Treatment of Malignant Hematological Diseases" by the Chinese Society of Clinical Oncology (CSCO) as a Class I recommendation for first-line stratified treatment of myelofibrosis [1]